Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440308 | 1.00 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CYP3A4MAPT | |
| SCHEMBL17440248 | 1.00 | CHRM2 (0.40) | CHRM2CHRM4CHRM3CYP3A4MAPT | |
| SCHEMBL9550332 | 0.83 | CHRM2 (0.44) | CHRM2CHRM4CHRM3CYP3A4MAPT | |
| SCHEMBL15653898 | 0.82 | GABRR1 (0.34) | CHRM2CHRM3CYP3A4MAPTKDM4E | |
| SCHEMBL15655634 | 0.82 | GABRR1 (0.34) | CHRM2CHRM3CYP3A4MAPTKDM4E | |
| SCHEMBL15655766 | 0.82 | GABRR1 (0.34) | CHRM2CHRM3CYP3A4MAPTKDM4E | |
| SCHEMBL28488918 | 0.79 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CYP3A4MAPT | |
| SCHEMBL13738379 | 0.78 | CHRM2 (0.39) | CHRM2CHRM4CHRM3CYP3A4SLC6A4 | |
| SCHEMBL12631508 | 0.78 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CYP3A4 | |
| SCHEMBL739390 | 0.78 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| US-9908895-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 4866/4885CHRM4 4843/4885CHRM3 4808/4885 |
| US-20160015695-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 4866/4885CHRM4 4843/4885CHRM3 4808/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | CHRM2 4866/4885CHRM4 4843/4885CHRM3 4808/4885 |
| US-20160024109-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CHRM2 4866/4885CHRM4 4843/4885CHRM3 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.